Charles River Laboratories International, Inc.
General ticker "CRL" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $9.0B (TTM average)
Charles River Laboratories International, Inc. follows the US Stock Market performance with the rate: 52.4%.
Estimated limits based on current volatility of 1.4%: low 269.32$, high 276.72$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 19700 (-2.0%) as of 2025
- US accounted for 55.3% of revenue in the fiscal year ended 2024-12-28
- Top business risk factors: Contract termination, Cybersecurity threats, Regulatory and compliance, Supply chain disruptions, Acquisition/divestiture risks
- Current price 10.1% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-27 to 2027-12-27
- 2025-12-27 to 2026-12-27 estimated range: [169.88$, 247.87$]
- 2026-12-27 to 2027-12-27 estimated range: [170.85$, 250.76$]
Financial Metrics affecting the CRL estimates:
- Positive: with PPE of 19.4 at the end of fiscal year the price was neutral
- Positive: 0.56 < Operating profit margin, % of 0.63
- Positive: 42.26 < Shareholder equity ratio, % of 44.35 <= 49.86
- Positive: Interest expense per share per price, % of 1.08 <= 1.42
- Positive: 6.77 < Operating cash flow per share per price, % of 7.47
- Positive: Industry inventory ratio change (median), % of -0.03 <= 0
- Positive: -51.61 < Industry operating profit margin (median), % of -17.56
- Positive: Inventory ratio change, % of 1.42 <= 4.02
Short-term CRL quotes
Long-term CRL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-28 | 2025-12-27 |
|---|---|---|---|
| Operating Revenue | $4,129.41MM | $4,049.99MM | $4,015.38MM |
| Operating Expenses | $3,512.15MM | $3,822.64MM | $3,990.22MM |
| Operating Income | $617.26MM | $227.35MM | $25.16MM |
| Non-Operating Income | $-35.98MM | $-134.23MM | $-124.67MM |
| Interest Expense | $136.71MM | $126.29MM | $107.03MM |
| Income(Loss) | $581.28MM | $93.11MM | $-99.50MM |
| Taxes | $100.91MM | $67.82MM | $42.66MM |
| Net Income(Loss)* | $474.62MM | $22.20MM | $-144.34MM |
| Stockholders Equity | $3,596.88MM | $3,461.50MM | $3,164.63MM |
| Inventory | $380.26MM | $278.54MM | $299.10MM |
| Assets | $8,195.00MM | $7,528.35MM | $7,135.42MM |
| Operating Cash Flow | $683.90MM | $734.58MM | $737.65MM |
| Capital expenditure | $318.53MM | $232.97MM | $219.15MM |
| Investing Cash Flow | $-563.15MM | $-245.09MM | $-209.32MM |
| Financing Cash Flow | $-85.52MM | $-550.93MM | $-536.73MM |
| Earnings Per Share** | $9.27 | $0.43 | $-2.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.